The bill amends Section 5030.1 of the Oklahoma Statutes regarding the Medicaid Drug Utilization Review Board, which is responsible for overseeing drug utilization programs within the state Medicaid program. Key modifications include changes to the appointment process for board members, specifically reducing the number of physician candidates submitted by the Oklahoma State Medical Association from six to three. Additionally, the bill updates the terminology used in the statute, such as changing "Pharmaceutical Association" to "Pharmacists Association" and "vice-chair" to "vice chair."

The composition of the board remains the same, consisting of ten members, including physicians, pharmacists, a lay community representative, and a pharmaceutical industry representative. The bill also establishes term lengths for members, with a mix of two-year and three-year terms to ensure staggered appointments. Furthermore, it mandates compliance with the Oklahoma Open Meeting Act and the Administrative Procedures Act for board meetings and proceedings. The act is set to take effect on November 1, 2025.